Published: July 2023

Key policies recommended to expand access and lower insulin prices

Consumer Action and dozens of other advocacy organizations joined in a letter urging Majority Leader Schumer to include key policies to expand access and lower insulin prices in the anticipated drug pricing package.

Consumer Action was one of 40 organizations—all committed to advancing access to affordable medicines for patients in the United States—to sign on to a letter to Majority Leader Schumer, urging him to include key policies to expand access and lower insulin prices in the anticipated drug pricing package.The advocates pointed out that to deliver the relief that insulin-dependent patients need and put an end to insulin profiteering, the legislation advanced out of the Senate must: 1) Ensure people with private insurance and those without insurance, who are most vulnerable to rationing, have access to the insulin they need; 2) Stop insulin manufacturers from charging excessive prices; and 3) Prevent anticompetitive tactics by drug corporations and middlemen from interfering with patient access to lower-priced insulin products, including biosimilars. Despite reforms advanced by the 117th Congress and concessions by insulin manufacturers that reduced drug prices and expanded access to lifesaving treatments like insulin, more than a million people in the U.S. still must ration insulin, including a disproportionately high number of Black Americans who require insulin (23.2%), compared with 16% of Hispanic and White Americans.

Lead Organization

Public Citizen

More Information

Click here to read the letter.

Download PDF

No Download Available